Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case

BACKGROUND: Patients with advanced salivary gland malignancies (SGCs) have few therapy options. Although results from newly published trials suggest that checkpoint inhibition may be useful in a subgroup of patients, there are no clear criteria for PD-L1 score in SGCs. Chemotherapy benefits were obs...

Descripción completa

Detalles Bibliográficos
Autores principales: Farhat, Raed, Asna, Noam, Avraham, Yaniv, Khater, Ashraf, Asakla, Majd, Safia, Alaa, Szvalb, Sergio, Elkhatib, Nidal, Merchavy, Shlomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142722/
https://www.ncbi.nlm.nih.gov/pubmed/35624380
http://dx.doi.org/10.1007/s12672-022-00502-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142722/
https://www.ncbi.nlm.nih.gov/pubmed/35624380
http://dx.doi.org/10.1007/s12672-022-00502-4

Ejemplares similares